Liver Cancer News and Research

RSS

Liver cancer is more common in older people. Over half of people newly diagnosed with liver cancer are age 65 and over. Liver cancer is more common in men than in women. Liver cancer rates are highest among Asians and Pacific Islanders, most likely because of higher prevalence of viral Hepatitis infection. Liver cancer rates are lower among whites than Blacks or Asians and Pacific Islanders. At this time, we do not know exactly what causes cancer of the liver. There are several different types of liver cancer. The most common type is associated with long-term excessive alcoholic beverage use, scarring of the liver (cirrhosis), and Hepatitis B virus or Hepatitis C virus infection. Long-term use of anabolic steroids can also increase the risk of getting liver cancer. Smoking is also believed to increase the risk of getting liver cancer.

NVHR welcomes national HIV/AIDS strategy that recognizes better care for HIV/AIDS, viral hepatitis patients

With millions of Americans living with HIV/AIDS, chronic viral hepatitis, or a combination of both, the National Viral Hepatitis Roundtable welcomes the Administration's recognition of the need for better care coordination and integration of services for these individuals and supports recommendations contained within the new National HIV/AIDS strategy released yesterday in Washington.

15 Jul 2010

Amorfix grants Biogen Idec exclusive worldwide rights to lead ALS monoclonal antibodies

Amorfix Life Sciences Ltd. today announced that it has entered into a licensing agreement granting Biogen Idec exclusive worldwide rights to Amorfix's lead amyotrophic lateral sclerosis (ALS) monoclonal antibodies. The antibodies have shown efficacy in animal models of ALS and Biogen Idec will now, at its expense, complete the development and prepare for clinical trials.

15 Jul 2010

Samsung Medical Center, Pfizer form research partnership

Samsung Medical Center and the world's leading bio-pharmaceutical company Pfizer Inc. announced that they have formed a research partnership to jointly analyze tumors from Korean patients to generate gene expression profiles and that may ultimately direct therapies and enhance clinical outcomes in the patients with liver cancer.

14 Jul 2010

The Samuel Waxman Cancer Research Foundation announces research grants totaling $1.54 million

The Samuel Waxman Cancer Research Foundation (SWCRF) has awarded 13 collaborative research grants and 3 individual research grants, totaling $1.54 million. The 16 grants represent a portion of the science grant program at the Foundation, which will award more than $2 million this year to cancer research.

14 Jul 2010

Amorfix Life Sciences uses A(4) test to detect accumulation of Abeta in mouse models of AD

Amorfix Life Sciences, a company focused on treatments and diagnostics for misfolded protein diseases including Alzheimer's disease, has used its A(4) test to compare the rate of accumulation of aggregated Abeta in the brain tissue of various mouse models of AD. Amorfix presented this new data at the International Conference on Alzheimer's Disease this week.

13 Jul 2010

Interim progress from Phase III TeloVac study of GV1001 vaccine announced

KAEL-GemVax, a leading oncology vaccine company, today announced, through its subsidiary GemVax A.S, encouraging interim progress from the UK-based Phase III TeloVac study of its anti-telomerase therapeutic cancer vaccine GV1001 in pancreatic cancer. The company also strongly believes GV1001 has major "blockbuster" potential as a universal therapeutic cancer vaccine and is developing a strong pipeline for other indications, including lung and liver cancer and melanoma.

12 Jul 2010

DGP/tTG Screen assay may be best initial test for suspected celiac disease: Study

Diagnosis of celiac disease is based on a characteristic enteropathy in an intestinal biopsy and evidence that these changes are gluten-triggered. The appropriate use of simpler and more accurate tools would add reliability to the diagnosis of celiac disease. Thus, the celiac disease-related serology might have a key role in defining new diagnostic standards for celiac disease.

9 Jul 2010

Study suggests Perfusion CT as noninvasive tool in diagnosis of hepatic toxicity

Liver damage is common in patients with tumor following chemotherapy. Although early liver damage causes no symptoms and is reversible in most patients, it occasionally progresses to more severe liver impairment, which may be irreversible, it is thus necessary to demonstrate the presence and severity of drug-related parenchymal changes.

9 Jul 2010

Early knowledge of HCC response to TACE determines treatment success: Research article

Early knowledge of hepatocellular carcinoma response to transcatheter arterial chemoembolization is crucial for determining treatment success, timing of repeat treatment, and patient prognosis. Currently, magnetic resonance imaging is used 1-3 mo after treatment to evaluate anatomical tumor response, based upon changes in tumor size and contrast-agent enhancement. Alternatively, diffusion-weighted imaging can be used as a functional imaging technique to depict thermally induced motion of water molecules.

9 Jul 2010

Local anesthetics have potential therapeutic effects on IBD: Research article

Inflammatory bowel disease is a disease of the gastrointestinal tract, mainly the intestines that may occur in the people who have genetic potential with a contribution of environmental factors. There has been no definitive medical treatment and drugs usually help the symptoms just to relieve.

8 Jul 2010

Researchers evaluate safety and feasibility of STARR procedure for ODS

Obstructed defecation syndrome represents a widespread clinical problem which frequently affects middle-aged females. Nevertheless, many of the previously established techniques are unsuitable for patients with ODS associated with simultaneous rectocele and rectal intussusception. Notably, STARR has been proposed as an alternative operation and a relatively noninvasive surgical technique for this difficult problem.

8 Jul 2010

Study reveals X+ allele of APOB gene as another risk factor of gallstone formation after gastrectomy

The cause of higher incidence of gallstone after radical gastrectomy still remains unknown. Almost all previous studies have attributed gallstone formation to gallbladder motility disorder after gastrectomy, But this theory cannot completely explain it. Is there any other risk factor of gallstone formation after gastrectomy?

8 Jul 2010

Report investigates clear cell ICC

Intrahepatic cholangiocarcinoma is a cancer of the bile duct in the liver. The clear cell subtype of ICC is a rare cancer; until now, only 8 cases have been reported. The number of reports is so small that a detail description of clear cell ICC is valuable.

8 Jul 2010

Common glucose test accurately predicts Type II adult-onset diabetes, study finds

A common test to diagnose gestational diabetes -- a temporary condition which can harm both mother and child if left untreated -- also has predictive power for Type II adult-onset diabetes, a new Tel Aviv University study finds.

8 Jul 2010

TWINCORE researchers develop new model approaches for HCV research

The hepatitis C virus is highly specialised. We humans are its natural hosts. The only other living organisms that could be infected with the hepatitis C virus in the lab are chimpanzees. Nevertheless it is - from the viewpoint of the virus - highly successful: around 170 million people are chronically infected with the virus. And with the chronic infection the risk of developing liver cancer also increases.

7 Jul 2010

Amorfix partners with reMYND to offer A4 amyloid testing services

Amorfix Life Sciences Ltd. and reMYND NV today announced the signing of a partnership agreement to offer the Amorfix A4 amyloid testing service to reMYND's contract research clients. reMYND's contract research business offers an extensive portfolio of preclinical in-vivo efficacy, pharmacokinetic and safety testing of experimental Alzheimer therapies using proprietary mouse models of Alzheimer's disease (AD).

6 Jul 2010

Virus related to hepatitis C discovered in Asian bats

Viral hepatitis affects more than 500 million people worldwide and is a cause of liver failure and liver cancer. While vaccines are available for hepatitis A and B, this is not the case for hepatitis C, which affects as much as two percent of the population in the U.S. Scientists today are reporting discovery of a virus related to hepatitis C in Asian bats, which may provide insights into the origins of the hepatitis C virus and into the mechanisms by which infectious diseases move from other species to humans.

2 Jul 2010

Study investigates efficacy of SWV measurement in evaluation of NASH pathophysiology using ultrasound

Nonalcoholic steatohepatitis (NASH) is manifestation of metabolic syndrome in the liver and is a pandemic over the globe especially in the developed countries, based on a high calorie diet and sedentary life style. As in the other types of chronic hepatitis, collagen fibers continuously accumulate in the liver through the course of NASH toward cirrhosis and hepatocellular carcinoma development.

29 Jun 2010

BioAlliance Pharma presents abstracts on Loramyc, clonidine Lauriad at MASCC/ISOO 2010 symposium

BioAlliance Pharma SA, a company dedicated to the supportive care and treatment of cancer patients, has presented 2 abstracts on Loramyc® and clonidine Lauriad® at the MASCC/ISOO 2010 International Symposium (Vancouver, June 24-26, 2010). These two products belong to the supportive care pipeline of BioAlliance Pharma.

29 Jun 2010

Experts to discuss latest trends in treatments, diagnostic techniques for managing HCC

Today, world renowned experts have assembled in Dubrovnik, Croatia to discuss the latest trends in treatment and cutting edge research in diagnostic techniques that will shape the future management of hepatocellular carcinoma - the third most common cause of cancer-related death globally, and a leading cause of death among patients with liver cirrhosis.

28 Jun 2010

Liver Cancer News and Research

Further Reading

NVHR welcomes national HIV/AIDS strategy that recognizes better care for HIV/AIDS, viral hepatitis patients

Amorfix grants Biogen Idec exclusive worldwide rights to lead ALS monoclonal antibodies

Samsung Medical Center, Pfizer form research partnership

The Samuel Waxman Cancer Research Foundation announces research grants totaling $1.54 million

Amorfix Life Sciences uses A(4) test to detect accumulation of Abeta in mouse models of AD

Interim progress from Phase III TeloVac study of GV1001 vaccine announced

DGP/tTG Screen assay may be best initial test for suspected celiac disease: Study

Study suggests Perfusion CT as noninvasive tool in diagnosis of hepatic toxicity

Early knowledge of HCC response to TACE determines treatment success: Research article

Local anesthetics have potential therapeutic effects on IBD: Research article

Researchers evaluate safety and feasibility of STARR procedure for ODS

Study reveals X+ allele of APOB gene as another risk factor of gallstone formation after gastrectomy

Report investigates clear cell ICC

Common glucose test accurately predicts Type II adult-onset diabetes, study finds

TWINCORE researchers develop new model approaches for HCV research

Amorfix partners with reMYND to offer A4 amyloid testing services

Virus related to hepatitis C discovered in Asian bats

Study investigates efficacy of SWV measurement in evaluation of NASH pathophysiology using ultrasound

BioAlliance Pharma presents abstracts on Loramyc, clonidine Lauriad at MASCC/ISOO 2010 symposium

Experts to discuss latest trends in treatments, diagnostic techniques for managing HCC

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Latest News